Deane et al reported that the administration of a synthetic analogue of human GLP-1, exenatide, was associated with a reduction in hypoglycaemic episodes and postprandial glycaemic excursions in ambulant type 2 diabetic patients [25]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.